Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

The MA.34/Aphinity study -- A randomized multicentre, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer -- was closed to further accrual as of June 28, 2013.

A memo regarding trial closure has been posted on the Canadian Cancer Trials Group MA.34 trial specific website.